Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
4(66.7%)
Phase 1
2(33.3%)
6Total
Phase 2(4)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT00394667Phase 2Completed

Effect of Tesofensine on Weight Reduction in Patients With Obesity.

Role: lead

NCT01023282Phase 1Completed

Safety and Tolerability Study Evaluating ACR325 in Parkinson's Disease Patients

Role: lead

NCT00481104Phase 2Completed

Evaluation of Long Term Safety of Tesofensine in Patients With Obesity

Role: lead

NCT00428415Phase 1Completed

Effect of Tesofensine on Energy Balance in Humans.

Role: lead

NCT00258622Phase 2Completed

NS1209 and Lidocaine in Patients With Peripheral Neuropathic Pain

Role: collaborator

NCT00467428Phase 2Completed

Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder

Role: lead

All 6 trials loaded